药明康德持续回馈股东，中期分红规模进一步提升至人民币15.1亿元

美通社08-31

上海2026年8月31日 /美通社/ -- 为全球医药及生命科学行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司（股票代码：603259.SH/2359.HK）派发2026年中期现金红利。继2025年首次实施中期分红（人民币10.3亿元）后，公司2026年中期分红规模进一步提升至人民币15.1亿元。在加速推进全球产能和能力建设的同时，公司不断回馈股东...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2663028773?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-31 08:00","share_image_url":"https://static.laohu8.com/7d5258e5fa9d58069a293859983c0a71","id":"2663028773","market":"hk","top_or_hot":-1,"title":"药明康德持续回馈股东，中期分红规模进一步提升至人民币15.1亿元","media":"美通社","content":"<div>\n<p>上海2026年8月31日 /美通社/ -- 为全球医药及生命科学行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司（股票代码：603259.SH/2359.HK）派发2026年中期现金红利。继2025年首次实施中期分红（人民币10.3亿元）后，公司2026年中期分红规模进一步提升至人民币15.1亿元。在加速推进全球产能和能力建设的同时，公司不断回馈股东...</p>\n\n<a href=\"http://wwwold.prnasia.com/story/archive/5036575_ZH36575_1\">网页链接</a>\n\n</div>\n","source":"prnasia","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>药明康德持续回馈股东，中期分红规模进一步提升至人民币15.1亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n药明康德持续回馈股东，中期分红规模进一步提升至人民币15.1亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-31 08:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://wwwold.prnasia.com/story/archive/5036575_ZH36575_1><strong>美通社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>上海2026年8月31日 /美通社/ -- 为全球医药及生命科学行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司（股票代码：603259.SH/2359.HK）派发2026年中期现金红利。继2025年首次实施中期分红（人民币10.3亿元）后，公司2026年中期分红规模进一步提升至人民币15.1亿元。在加速推进全球产能和能力建设的同时，公司不断回馈股东...</p>\n\n<a href=\"http://wwwold.prnasia.com/story/archive/5036575_ZH36575_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02359","symbol_name":"药明康德","start_time":0,"source_url":"http://wwwold.prnasia.com/story/archive/5036575_ZH36575_1","article_id":"2663028773","we_media_id":null,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5036575_ZH36575_1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2663028773","pubTimestamp":1788134400,"columns":[],"sourceInfo":{"source_id":"prnasia","name":"美通社"},"weMediaInfo":null,"summary":"上海2026年8月31日 /美通社/ -- 为全球医药及生命科学行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司派发2026年中期现金红利。继2025年首次实施中期分红后，公司2026年中期分红规模进一步提升至人民币15.1亿元。在加速推进全球产能和能力建设的同时，公司不断回馈股东，共享公司价值。","collect":0,"end_time":0,"defaultTopTitle":"prnasia.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603259":"药明康德","02359":"药明康德","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","LU1997245177.USD":"安联神洲A股基金","VIG":"股利增长指数ETF-Vanguard","BK4588":"碎股","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1141":"生命科学工具和服务","LU1808992512.USD":"AB ALL CHINA EQUITY PORTFOLIO \"A\" (USD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0700851271.USD":"NINETY ONE GSF EMERGING MARKETS MULTI-ASSET \"A\" (USD) ACC","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","LU1303224171.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC","BK1576":"医药外包概念","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0052750758.USD":"富兰克林中国基金A Acc","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU0611395673.USD":"NINETY ONE GSF EMERGING MARKETS EQUITY \"A\" (USD) ACC","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU0469268626.HKD":"AB FCP I-ASIA EX JAPAN EQUITY PTF(AD","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU1046422090.SGD":"Fidelity Pacific A-SGD","BK4585":"ETF&股票定投概念","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","BK0216":"研究试验","BK1583":"高瓴概念","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD"},"translate_title":"WuXi AppTec continues to reward shareholders, further increasing its interim dividend to RMB 1.51 billion.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":0.9,"VIG":1.5,"02359":1.5},"content_text":"上海2026年8月31日 /美通社/ -- 为全球医药及生命科学行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司（股票代码：603259.SH/2359.HK）派发2026年中期现金红利。继2025年首次实施中期分红（人民币10.3亿元）后，公司2026年中期分红规模进一步提升至人民币15.1亿元。在加速推进全球产能和能力建设的同时，公司不断回馈股东，共享公司价值。 A股股东请见公司相关公告：2026年半年度A股权益分派实施公告 H股股东请见公司相关公告：有关支付2026年中期股息分派的公告 关于药明康德 药明康德（股票代码：603259.SH/2359.HK）是全球医药及生命科学行业值得信赖的合作伙伴和重要贡献者，致力于通过提供一体化、端到端的新药研发和生产服务，推动全球医药健康创新。公司在亚洲、欧洲、北美等地均设有运营基地，依托独特的\"CRDMO\"业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来突破性的治疗方案。目前，公司的赋能平台正承载着来自全球30多个国家的合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现\"让天下没有难做的药，难治的病\"的愿景。更多信息，请访问公司网站：。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2663028773","isCrawlerRequest":true}